Virpax Pharmaceuticals, Inc. has taken a significant step towards its capital raising efforts by filing a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). The filing, identified by File No. 333-278796, was made on May 14, 2024. A.G.P./ALLIANCE GLOBAL PARTNERS, acting as the Sole Placement Agent, has formally requested the SEC to declare the Registration Statement effective by 5:00 p.m. Eastern Time on the same day, or as soon as possible thereafter. This move is in accordance with Rule 461 of the Securities Act of 1933. The company has also indicated that, in line with Rule 460, it expects to distribute copies of the Preliminary Prospectus dated May 13, 2024, to a variety of potential investors to ensure adequate distribution. A.G.P./ALLIANCE GLOBAL PARTNERS has confirmed compliance with its obligations under Rule 15c2-8 of the Securities Exchange Act of 1934, which includes the delivery requirements of the Preliminary Prospectus to prospective investors.

Virpax Pharmaceuticals, Inc. has taken a significant step towards its capital raising efforts by filing a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). The filing, identified by File No. 333-278796, was made on May 14, 2024. A.G.P./ALLIANCE GLOBAL PARTNERS, acting as the Sole Placement Agent, has formally requested the SEC to declare the Registration Statement effective by 5:00 p.m. Eastern Time on the same day, or as soon as possible thereafter. This move is in accordance with Rule 461 of the Securities Act of 1933. The company has also indicated that, in line with Rule 460, it expects to distribute copies of the Preliminary Prospectus dated May 13, 2024, to a variety of potential investors to ensure adequate distribution. A.G.P./ALLIANCE GLOBAL PARTNERS has confirmed compliance with its obligations under Rule 15c2-8 of the Securities Exchange Act of 1934, which includes the delivery requirements of the Preliminary Prospectus to prospective investors.